Mineralys Therapeutics, Inc. (MLYS) Tops Q2 EPS by 41c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($0.31), $0.41 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• SanDisk upgraded at JPMorgan after investor day; shares climb